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Abstract
Background: Since 1980, about 100 types of congenital disorders of glycosylation (CDG) have been reported
representing an expanding group of inherited disorders. ALG8-CDG (= CDG-Ih) is one of the less frequently reported
types of CDG, maybe due to its severe multi-organ involvement with coagulation disturbances, edema, massive
gastrointestinal protein loosing enteropathy, cataracts, and often early death. We report three additional patients,
provide an update on two previously reported, and summarize features of ten patients reported in literature.
Results: Of 15 ALG8-CDG patients, three were homozygous and 12 compound heterozygous. There were multiple
prenatal abnormalities in 6/12 patients. In 13/15, there were symptoms at birth, 9/15 died within 12 months. Birth
weight was appropriate in 11/12, only one was small for gestational age. Prematurity was reported in 7/12. Hydrops
fetalis was noticed in 3, edemas in 11/13; gastrointestinal symptoms in 9/14; structural brain pathology, psychomental
retardation, seizures, ataxia in 12/13, muscle hypotonia in 13/14. Common dysmorphic signs were: low set ears,
macroglossia, hypertelorism, pes equinovarus, campto- and brachydactyly (13/15). In 10/11, there was coagulopathy,
in 8/11 elevated transaminases; thrombocytopenia was present in 9/9. Eye involvement was reported in 9/14. CDG
typical skin involvement was reported in 8/13.
Conclusion: In ALG8-CDG, isoelectric focusing of transferrin in serum or plasma shows an abnormal sialotransferrin
pattern. The diagnosis is confirmed by mutation analysis in ALG8; all patients reported so far had point mutations or
small deletions. The prognosis is generally poor. Thus, a timely and correct diagnosis is important for counselling.
Keywords: Congenital disorders of glycosylation, Isoelectric focusing of transferrin, Hydrops fetalis, Cataract,
Coagulopathy, Gastrointestinal symptoms
Background
Congenital disorders of glycosylation (CDG) involve a
rapidly growing group of metabolic diseases that are
caused by genetic defects in the synthesis of glycopro-
teins [1]. The first two patients were diagnosed in 1980
by the Belgian pediatrician Jaak Jaeken [2]. To date,
some 100 CDG have been identified [1, 3] (with over
700 patients reported worldwide), and about 50 of these
can be identified via isoelectric focusing of transferrin
[1, 3–5]. CDG have been divided in four groups: (1)
disorders of protein N-glycosylation, (2) disorders of
protein O-glycosylation, (3) disorders of lipid and GPI
(glycosylphosphatidylinositol) anchor glycosylation, and
(4) disorders of multiple glycosylation pathways [5, 6]. De-
fects in protein N-glycosylation are divided into two sub-
groups: CDG-I disorders comprise defects in the glycan
synthesis (cytosol and endoplasmic reticulum (ER)), and
CDG-II disorders defects in glycan processing (Golgi ap-
paratus) [1]. In 2008, Jaeken et al. proposed a nomencla-
ture that refers to the gene name under the umbrella
name of CDG, e.g. PMM2-CDG, ALG8-CDG, etc. [7].
CDG affect multiple organ systems, the severity of symp-
toms is highly variable and it shows a broad clinical
spectrum with considerable overlap [1, 3].
ALG8-CDG (OMIM #608104) is due to inactivating
mutations in the ALG8 gene encoding dolichyl-phosphate-
glucose 1-mannose 9-N-acetylglucosamine (Dol-P-Glc:Glc
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(2)Man (9)GlcNAc(2)-PP-Dol-alpha-2) glucosyltransferase
(= glucosyltransferase 2) in the ER, an enzyme that at-
taches the second glucose residue to dolichol-PP-glycans
in the ER [8]. ALG8-CDG is a CDG form with dysmorph-
ism (retrognathia, low-set ears, pes equinovarus), muscular
hypotonia, hepatomegaly, coagulopathy (thrombocytopenia),
edema and ascites (including fetal hydrops), cardiorespi-
ratory problems, and protein-losing enteropathy (watery
diarrhea) [8]. Cataracts (ocular findings) have only been
reported in ALG8-CDG, ALG12-CDG (CDG-Ig), other
subtypes in early LLO (lipid-linked oligosaccharides)
synthesis (like SRD5A3-CDG) and some unclassified
CDG [9, 10].
Here, we describe three severely affected neonates
from two families with ALG8-CDG with congenital cata-
racts, and provide an update on two previously reported
children with congenital cataracts [11], where ALG8-
CDG was confirmed recently. In addition, we summarize
the clinical and biochemical characteristics of these five
patients, further ten published patient reports and present
a review of the literature.
Clinical reports - patients
Patient 1
The first child of healthy, non-consanguineous, Caucasian
parents, was born in the 34th gestational week after oligo-
hydramnios in pregnancy. 15 min after birth, the boy died
of severe respiratory failure due to pulmonary hypoplasia
with alveolar dysgenesis. Clinical examination showed
low-set ears, macroglossia, bilateral pes equinovarus, hy-
poplastic thorax, generalized edema, and a pale gray mot-
tled skin. Bilateral cataracts were noted. Autopsy showed
renal tubular dysgenesis, cerebral edema and ascites.
Patient 2
The second boy, brother of Patient 1, was born at
35 weeks of gestation by Caesarean section because of a
pathological cardiotocogram (CTG). Pregnancy was
complicated by intrauterine hydrops fetalis with pericar-
dial effusion and ascites as well as oligohydramnios.
Birth weight was 2700 g (50th centile), head circumfer-
ence 34.5 cm (75th centile) and length 48 cm (75th cen-
tile). The Apgar scores were 3/7/8 and umbilical cord
pH was 7.36. Because of respiratory insufficiency, the
boy was mechanically ventilated for four days. Dysmorph-
ism (wide-open fontanel, incomplete bilateral cataract,
low-set ears, hypertelorism, macroglossia, retrognathia),
generalized edema, a pale mottled skin as well as pro-
nounced muscular hypotonia were present. Laboratory
investigation showed thrombocytopenia (lowest value
19,000/μL, decreased prothrombin time (PT)(40 %; nl 74–
108) and increased partial thromboplastin time (PTT)
(>200 s.; nl 28–49)).
After initial stabilization the patient’s general condition
worsened in the third week of life. He developed watery
diarrhoea and vomiting, and subsequently acute renal
failure with anuria and ascites. His condition deterio-
rated and at 34 days of life he died due to cardiocircula-
tory failure.
Patient 3
In 1996, our group reported the first, albeit at that time
unclassified, ALG8-CDG patient (Table 1) [11]. The girl
was the second child of healthy, unrelated, Caucasian
parents and died at the age of 30 months. She presented
with severe psychomotor disability, microphthalmy, cata-
ract, brachydactyly, cortical atrophy, slight elevation of
serum transaminases and blood coagulation abnormalities.
Patient 4
Six years later, a brother of Patient 3 (Fig. 1a,b) [11] was
born after an uneventful pregnancy by Caesaran section
in the 36th gestational week because of breech presenta-
tion. Birth weight was 2590 g, length 48 cm and head
circumference 33 cm (all 25th centile). The boy presented
as a floppy infant, with bilateral congenital cataracts and
multiple dysmorphic features such as a prominent fore-
head, a wide fontanelle, macroglossia, dysplastic ears, a
high-arched palate, inverted nipples, peculiar fat pads of
the buttocks, and short fingers and toes. Cyanotic apnoeas
were repeatedly present from the 4th day of life. Labora-
tory tests showed slight elevation of transaminases and
transient hypoalbuminaemia, as well as pathological co-
agulation (with prolonged PTT (partial thromboplastin
time), low antithrombin III, and several reduced coagula-
tion factors). He suffered from vitreous bleeding during
cataract operation and died at the age of four years from
cardiac dysrhythmia.
Patient 5
This girl (Fig. 2a), sister of a healthy four year old girl,
was born in the 37th gestational week after an unevent-
ful pregnancy. Labour was induced because of a patho-
logical CTG. Birth weight was 3080 g (50th centile),
length 47 cm (10th centile) and head circumference
33 cm (25th centile), the Apgar scores were 8/9/10 and
arterial umbilical cord pH was 7.36. She was hospitalized
due to fluctuations of saturation, tachypnea and increased
inflammation parameters as well as thrombocytopenia
(lowest platelet count was 49 G/l; normal range: 223–
510 G/l), and was treated with antibiotics. During the first
days, she vomited repeatedly. She showed mild micro-
cephaly, facial dysmorphism (bilateral cataract, low-set
ears, relative macroglossia), fat pads on the arms (Fig. 2b)
and thighs, hypotonia with dystonic posturing, hepatosple-
nomegaly, and persisting primary vitreous artery (Fig. 3).
Routine laboratory parameters (including coagulation
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Table 1 Findings in 15 patients with ALG8 deficiency
Skladal
[11]
Charlwood
[14]
Chantret
[8]
Schollen
[15]
Eklund
[9]
Vesela
[16]
Stölting
[17]
Sorte
[18]
Funke [19]
Kouwenberg
[20]
Patients 1, 2, 5
Sex F M M F F M M F M F F M M M F
Prenatal Data
IUGR / / Yes / Yes No No No No No Yes No No No No
Oligohydramnios / / Yes / Yes No No Yes No No No No Yes Yes No
Hydrops fetalis / / ND / / / / Yes No No / No Yes Yes No
Neonatal data
Weeks of
gestation
/ 36 w (CS) 35 w (CS) / / 35 w 37 w 29 w (CS) At term At term 39 w (CS) 35 w 34 w (CS) 35 w (CS) 37 w (CS)
Birth weight / 2,590 g 2,280 g / / 2,920 g 3,070 g 1,420 g 3,980 g 3,680 g 2,210 g 2,920 g 2,570 g 2,700 g 3,080 g
Clinical
symptoms
Ascites/edemas / Yes Yes Yes Yes Yes Yes No No Yes Yes Yes Yes Yes
Onset of first
symptoms
From
birth
From
birth
4 months From
birth
8 weeks From
birth
From
birth
From
birth
From
birth
From
birth
From
birth
From
birth
From
birth
From
birth
Dysmorphism Yes Yes No Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
Gastrointestinal
symptoms
/ Yes Yes No Yes Yes Yes No No Yes Yes No Yes Yes
Brain
involvement
Yes Yes No / Yes Yes Yes Yes Yes Yes Yes / Yes Yes
Hypotonia / Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Skin involvement / Yes No / Yes No No Yes Yes Yes Yes No No Yes
Eye symptoms Cataract No Retinopathy / No Cataract Optic
atrophy
No No Nystagmus No Cataract Cataract Cataract
Laboratory data
Thrombocytopenia / Yes / Yes Yes Yes Yes / / Yes Yes / Yes Yes
Coagulopathy Yes Yes Yes Yes ND Yes Yes / / Yes Yes / Yes No
Hyponatremia / Yes / Yes Yes Yes / / / / Yes Yes Yes Yes
Increased
transaminases
Yes Yes No / Yes Yes No / / Yes Yes / Yes No
H
öck
et
al.O
rphanet
Journalof
Rare
D
iseases
 (2015) 10:73 
Page
3
of
8
Table 1 Findings in 15 patients with ALG8 deficiency (Continued)
Survival 30 months 4 years 3 months >3 years 3 days 3 months 16 months 2 months >6 years >7 years 8,5 months 3 months 15 min 34 days 39 days
ALG8
mutations
/ Homozygous Comp.
het.
Comp.
het.
Comp.
het.
Comp.
het.
Homozygous Comp.
het.
Comp.
het.
Comp.
het.
Comp.
het.
Comp.
het.
/ Comp.
het.
Comp.
het.
Mutation 1
(genomic)
c.139A>C c.139A>C c.413delC c.139A>C c.673+4A>G c.139A>C c.139A>C c.845C>T c.845C>T c.799T>C c.673+4A>G c.139A>C c.139A>C
Mutation 1
(functional)
p.T47P p.T47P p.T138Kfs*19 p.T47P Splice
mutation
p.T47P p.T47P p.A282V p.A282V p.S267P Splice
mutation
p.T47P p.T47P
Mutation 2
(genomic)
c.139A>C c.96-2A>G c.396insA c.96-2A>G c.824G>A c.139A>C c.1090C>T c.1436delC c.1436delC c.808T>C c.824G>A c.1090C>T c.1219_1220delCT
Mutation 2
(functional)
p.T47P Splice
mutation
p.V133Sfs*3 Splice
mutation
p.G275D p.T47P p.R364* p.P479Lfs*6 p.P479Lfs*6 p.F270L p.G275D p.A364* p.L407Dfs*23
CS Cesarean section; ND not described or no information available; dysmorphism such as low-set ears, macroglossia, pes equinovarus, campto- and brachydactyly; gastrointestinal symptoms include diarrhea, vomiting,
protein-losing enteropathy; CNS defects include structural brain abnormalities, mental or psychomotor retardation, seizures; hypotonia presenting as floppy infant; skin involvement is abnormal fat distribution, wrinkly
skin, cutis laxa, inverted nipples; electrolyte disturbances refers to hyponatremia; exitus, death, when written as > years it means age at last follow-up, no further information on outcome, comp. het., compound
heterozygous
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parameters and thyroid function tests) were normal. Over
the next weeks, the girl deteriorated progressively with re-
current episodes of apneas often combined with bradycar-
dia. Electroencephalogram (EEG) showed a pathological
brain wave pattern with decreased brain activity. On day
38 of life, a pale skin and apneas were noted, with ventricu-
lar tachycardia. The girl died from cardiovascular arrest.
Methods
Serum transferrin isoelectrofocusing was performed as re-
ported [12]. Mutation analysis of the PMM2 and ALG8
genes was performed according to standard methods [1, 13].
In CDG, enzyme analyses are not available for all types
of defects in the pathway. When enzymatic analysis
lacks, lipid-linked oligosaccharides (LLO) in fibroblasts
Fig. 1 a,b Patient 4 at the age of 10 months - floppy infant, with multiple dysmorphic features such as a prominent forehead, wide fontanelle,
macroglossia, dysplastic ears, high palate, inverted nipples, short fingers and toes and a pale mottled skin, “fat pads” on arms and thighs [11]
Fig. 2 a,b Patient 5 at the age of 20 days - floppy infant, with intermittent dystonic posturing, and multiple dysmorphic features such as an
abnormal fat distribution on arms and thighs, macroglossia, low-set ears, additionally, cataracts and persisting primary vitreous artery were present
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can show characteristic profiles [13], narrowing down
the diagnosis of CDG. For confirmation of the diagnosis,
molecular genetic testing is necessary. Standard Sanger
sequencing was performed in all five patients. In the fu-
ture, with a better availability, exome or whole genome
sequencing methods might be helpful as well.
Results
In all our 5 patients, the plasma isoelectric focusing of
transferrin showed a type 1 pattern (CDG-I) and con-
firmed the clinical suspicion of an underlying CDG.
In Patient 4, sialotransferrins showed a type 1 pattern
(CDG-Ix). However, PMM activity in fibroblasts was
normal. Through enrollment in the Euroglycanet net-
work, ALG8-CDG was diagnosed in 2011 (homozygous
c.139A>C p.Thr47Pro). The parents are heterozygous.
In Patient 2 with prenatal hydrops, edema and cata-
ract, the serum transferrin type 1 pattern prompted us
to investigate ALG8 gene as a candidate. A founder mu-
tation was suspected as the family originated from the
same Tyrolean region where we previously had diag-
nosed another pair of siblings (Patient 3 and 4) with type
1 pattern and cataract [11]. Two heterozygous mutations
in the ALG8 gene were found in DNA extracted from fi-
broblasts of Patient 2 (c.139A>C in exon 2, p.Thr47Pro,
and c.1090C>T in exon 10, p.Arg364Ter), confirming the
diagnosis of ALG8-CDG.
The clinical similarity and plasma transferring type I
pattern prompted analysis of ALG8 gene in Patient 5.
This showed compound heterozygosity for the known
ALG8 mutation in exon 2, c.139A>C, p.Thr47Pro and a
newly described one in exon 11, c.1219_1220delCT,
p.Leu407Aspfs*23.
Both the c.139A>C and c.1090C>T mutations are
known disease causing mutations described previously,
c.1219_1220delCT is a frame shift mutation with subse-
quent premature stop codon formation.
Of the 15 patients summarized here (3 newly described,
12 reported in literature [8, 9, 14–20] – including 2 pub-
lished by our group [11]), three are homozygous (includ-
ing one pair of siblings) and 12 compound heterozygous
(including three pairs of siblings). Of the 26 allels detected,
9 (35 %) are c.139A>C (Table 1). If we add the analyses of
the deceased siblings (Patient 1 and Patient 3), there
would be 30 alleles in total, and 12 (40 %) c.139A>C.
In summary, Table 1 shows features of 15 ALG8-CDG
patients in total. There are multiple prenatal abnormal-
ities in 6/12 patients: 3 had intrauterine growth retard-
ation, 5 oligohydramnios and 3 hydrops fetalis. In 13/15
patients symptoms were recorded at birth and 9/15 died
within the first year of life, showing the severity of ALG8
deficiency. Birth weight was appropriate for gestational
age in 11/12 patients and only one patient was small for
gestational age (birth weight <10th centile). Prematurity
(<37 weeks) was reported in 7/12 patients. Hydrops feta-
lis was noticed only in three patients, whereas edema
was present in 11/13. Common dysmorphic signs were:
low set ears, macroglossia, hypertelorism, pes equino-
varus, campto- and brachydactyly (13/15). Gastrointestinal
symptoms included diarrhea, vomiting, feeding problems
Fig. 3 Ocular sonography of Patient 5 at the age of 10 days - Persistent hyperplastic primary vitreous artery. A thin y-shaped membrane extends
from the optic disc to the posterior aspect of the opacified lens representing a remnant of the hyaloid vasculary system
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with failure to thrive, protein-losing enteropathy (9/14
patients). Brain involvement included psychomotor disabil-
ity, seizures, ataxia, and structural abnormalities (dilatation
of ventricles, corpus callosum hypoplasia, leukoencephalo-
pathy/leukodystrophy, cortical/cerebral atrophy) in 12/13
patients. Hypotonia/‘floppy infant’ was present in 13/14
patients. Thrombocytopenia was present in 9/9 patients.
Most patients had liver pathology: elevated serum trans-
aminases in 8/11 and abnormal clotting factors in 8/11.
Eye involvement (especially cataracts) was reported in 9/
14 patients and skin involvement like fat pads, wrinkly
skin, cutis laxa and inverted nipples was reported in 8/13
patients.
Discussion
ALG8-CDG is one of the less frequently reported CDG
syndromes. It affects an early step of protein glycosyla-
tion and in general has a poor prognosis. It was first re-
ported by Chantret et al. in 2003 [8]. There are twelve
patients described to date (Skladal et al. [11] (n = 2),
Charlwood et al. [14] (n = 1), Chantret et al. [8] (n = 1),
Schollen et al. [15] (n = 2), Eklund et al. [9] (n = 1),
Vesela et al. [16] (n = 1), Stölting et al. [17] (n = 2), Sorte
et al. [18] (n = 1), and one patient reported by both
Funke et al. [19] and Kouwenberg et al. [20] (Table 1).
In the majority of patients (13/15), the disease had a
neonatal onset and rapid progression. In 9/15 patients,
the outcome was fatal within the first year of life
(Table 1). So far, no adult patients (>18 years of age) af-
fected with this subtype have been reported [21].
We reviewed the most common clinical, laboratory
and genetic findings in the twelve previously reported
patients diagnosed with ALG8-CDG (Table 1), add here
the data of three additional patients with ALG8-CDG
(Patient 1,2 and 5), and provide an update on two previ-
ously reported patients (Patient 3 and 4). For the two pa-
tients reported by Charlwood et al. [14] and the two
reported by Skladal et al. (Patient 3 and 4) [11], the diag-
nosis of ALG8-CDG was provided years later.
In the series of 15 patients summarized in this paper,
there are four pairs of siblings (Schollen [15] plus the
patient reported by Charlwood et al [14], Stölting [17],
Patient 1/2, and Patient 3/4 in this paper) (Table 1),
reflecting an ascertainment bias for firstborns deceased
without diagnosis being established before a second af-
fected child was born.
Hydrops fetalis has also been described in PMM2-
CDG and ALG1-CDG [1]. In the patients described
here, it was present in the two brothers (Patient 1 and 2)
and in 1/12 additional patient reported in the literature
(Table 1). Hyponatremia reported in eight patients is
probably secondary to ascites/edema (11 patients). Un-
like other CDG types, cataracts (ocular findings) have
only been reported in ALG8-CDG, ALG12-CDG, other
subtypes in early LLO synthesis (like SRD5A3-CDG)
and some unclassified CDG [9, 10].
CDG are a clinically and genetically heterogeneous
group of disorders. Patients with ALG8-CDG show very
similar clinical features with neonatal onset and fatal
outcome within the first year of life. We believe that this
CDG disorder might be underdiagnosed. Early discrimina-
tive symptoms in ALG8-CDG patients are multisystem in-
volvement with dysmorphism, neurological symptoms and
cataracts in about 50 % of cases. Therefore, we suggest
screening for CDG sialotransferrins in serum or plasma in
all infants with early multi-organ involvement (such as
cataracts, non-immune hydrops, coagulopathy). Confirm-
ation of diagnosis requires molecular genetic testing.
The diagnosis of CDG is frequently delayed due to the
highly variable phenotype, with some cases showing sin-
gle organ involvement and others mimicking syndromes,
like skeletal dysplasia, cutis laxa syndrome, or congenital
muscle dystrophy.
In MPI-CDG (=CDG-Ib) (phosphomannose isomerase
deficiency), the protein-losing enteropathy and hypo-
glycaemia can be treated with an oral uptake of mannose
[22], in SLC35C1-CDG (=CDG-IIc), the leukocyte adhe-
sion deficiency can be treated with oral fucose [23], and
in PGM1 (Phosphoglucomutase 1 deficiency), treatment
with galactose leads to improved indexes of glycosylation
[24]. For ALG8-CDG, there is currently no curative treat-
ment available. However, establishing a molecular diag-
nosis is important for family counselling and prenatal
diagnosis [25].
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